InvestorsHub Logo
Followers 15
Posts 315
Boards Moderated 0
Alias Born 08/22/2020

Re: Euripides90 post# 47089

Thursday, 04/08/2021 1:33:27 PM

Thursday, April 08, 2021 1:33:27 PM

Post# of 50633
1) U.S.P.T.O.Maintenance Fee Storefront Link:

https://fees.uspto.gov/MaintenanceFees/fees/details?applicationNumber=10574163&patentNumber=7566567&caresActSelected=

IMMORTALIZED HEPATOCYTES
PATENT #
7566567
APPLICATION #
10574163
FILING DATE
03/29/2006
ISSUE DATE
07/28/2009
Payment Window Status
WINDOW
11.5 Year
STATUS
Closed
FEES
Paid
Window
First Day to Pay
Surcharge Starts
Last Day to Pay
Status
Fees
Statement
3.5 Year 07/28/2012 01/29/2013 07/29/2013 Closed Paid Statement
7.5 Year 07/28/2016 01/31/2017 07/28/2017 Closed Paid Statement
11.5 Year 07/28/2020 01/29/2021 07/28/2021 Closed Paid Statement
Patent Holder Information


Customer # 87008
Entity Status UNDISCOUNTED
Phone Number (408) 993-1800

Address MultiCell Technologies, Inc.
c/o David Lewis
1250 Aviation Avenue, Suite 200B
San Jose, CA 95110
UNITED STATES



2)
MCET's patent attorney David Lewis is the original attorney on record that filed the Immortalized Hepatocytes patent for MCET with the US Patent Office

FILING DATE
03/29/2006
ISSUE DATE
07/28/2009

Recently, MCET patent attorney Mr David Lewis paid the maintenance fee on 12-18-2020 for MCET immortalized Human Hepatocytes cell lines

This is the same Fa 2N-4 immortalized human hepatocytes cell line patent that multiple companies and universities have been infringing on for years without having a license agreement or paying any kind of royalties to MCET.

In fact, XenoTech had a contract to pay MCET $18,000,000 plus 3% of the revenue and then decided to terminate the contract. But come to find out they are still using this same cell line and also licensing Fa 2N-4 themselves without any agreement with MCET or without paying a dime for them infringing on their Patent.


3)
Click on the website below that shows MCET Fa 2N-4 cell line is still being sold by SEKISUI XENOTECH: (December 2020:)

SEKISUI XENOTECH WEBSITE:

https://www.xenotech.com/in-vitro-test-systems/cell-products/primary-human-hepatocytes/plateable/immortalized/


4)
2005 article showing relationship between MCET and XenoTech and other companies.

Click on link below to read full article:

https://www.businesswire.com/news/home/20051028005270/en/MultiCell-Develops-Improved-Cell-Culture-Media-Supplement-MFE-Supplement-A-Four-Immortalized-Hepatocyte-Posters-presented-at-ISSX

MultiCell Develops Improved Cell Culture Media Supplement, MFE Supplement A; Four Immortalized Hepatocyte Posters presented at ISSX
October 28, 2005 09:48 AM Eastern Daylight Time

LINCOLN, R.I.--(BUSINESS WIRE)--Oct. 28, 2005--MultiCell Technologies, Inc. (OTCBB: MCET) announced today that XenoTech LLC, MultiCell's marketing and manufacturing licensee, introduced an improved cell culture media supplement called MFE Supplement A on October 25th at the joint ISSX / JSSX Meeting in Hawaii and presented latest data on the cell line and media with a scientific poster presentation.

MultiCell's new exclusive culture media supplement enhances the sensitivity of the cells to detect CYP3A4 inducers, which improves the ability of the cells to detect those drug candidates that have a high potential to cause certain types of drug-drug interactions.

“Improving the dynamic range of CYP3A4 induction in immortalized human hepatocytes (Fa2N-4 cells)”


MultiCell's progenitor cells and immortalized liver cells are used by XenoTech, Pfizer, Bristol Myers Squibb and a growing number of other pharmaceutical companies to improve the safety profile of drugs by identifying early in the drug development program those drug candidates that can cause clinically significant enzyme induction and drug-drug interactions. The cells are available in a variety of formats (cryopreserved or ready to use plates) for testing drug candidates to help lower drug development costs and help prevent costly drug recalls. In June, MultiCell announced sales of its immortalized human hepatocytes (Fa2N-4 cells) in shrink-wrapped vials and plates, allowing purchase of cells without no-grow agreements. By opening the wrap, a user indicates acceptance of the no-grow terms of a one-time use license. The companies now recommend, for best results, ordering a complete package of hepatocytes, culture media, and supplement A. Call XenoTech at 1 (913) GET- P450 and ask for the current special package promotional offer.


5)
Published: 18 October 2016
Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytes
Methods Cell culture and labeling

Fa2N-4 cells (an immortalized normal hepatocyte cell line) were purchased from Xenotech (Lenexa, KS, USA), and Huh7, Hep3B, PLC/PRF/5, SNU475 and SNU449 (human hepatocellular carcinoma cell line) were obtained from the Korean Cell Line Bank (KCLB). Huh7.5 [14] was kindly provided by Charles M. Rice (Rockefeller University, New York, USA), and Huh6 [15] was kindly provided by Dr. Ralf Bartenschlager (University of Heidelberg, Germany). Cells were maintained at 37 °C with 95 % humidity and 5 % CO2. After cell attachment (3–6 h), serum-containing plating medium (XenoTech, Lenexa, KS, USA) was replaced with MFE serum free supporting Fa2N-4 cells (SF) medium (XenoTech) which are nutrient rich medium for maintaining Fa2N-4 cells in culture. This is a serum free medium. Huh7 cells (a human HCC cell line) were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, Gaithersburg, MD, USA) supplemented with heat-inactivated 10 % fetal bovine serum (FBS; Gibco) and antibiotics (Gibco) at 37 °C in a humidified incubator under 5 % CO2. For the 3D culture, 8 µl of Matrigel (BD Biosciences, San Jose, CA, USA) was pipetted directly onto the surface and carefully spread to avoid bubbles in 384 well culture plates (Greiner Bio-One, Monroe, NC, USA), then incubated at 37 °C until the Matrigel solidified. Trypsinized single cells from a monolayer were centrifuged at 1,000 rpm, resuspended in 30 ml of supporting culture medium, and plated onto the Matrigel-coated plates at a density of 2?×?103 cells/well. Cells were incubated for 30 min at 37 °C to settle onto the Matrigel, then 10 % Matrigel-Medium was slowly added to each well. After maintaining for 5 days, the Matrigel-Medium was replaced every 2 days.



Click on the link below for 2016 that shows multiple companies and Universities still use MCETs Patent.

https://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2816-x

6)

I would hope now, since MCET is finally having their Patent attorney pay this maintenance fee. That this would be a first step to go after everyone that has been infringing on all their parents

7)

MultiCell Technologies Inc., a Providence-based developer of therapeutics for the treatment of degenerative neurological diseases, has terminated the exclusive license agreement with XenoTech LLC of Kansas for "failure to meet minimum royalty obligations," according to company officials.

Link to article:

https://www.bizjournals.com/boston/blog/mass-high-tech/2006/02/multicell-cancels-distribution-deal-with.html

8) I have been reading/learning that some people sometimes sabotage something for self-interest. Example: A company that wants to outsource work, would find resistance or find some people trying to sabotage that deal trying to save their jobs.